Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes

Abstract

Data from a 20-week trial comparing insulin detemir and neutral protamine Hagedorn (NPH) insulin in insulin-naïve people with type 2 diabetes were analyzed using willingness-to-pay (WTP) data, a proxy for patient preference. The advantages of insulin detemir relative to NPH insulin with respect to a lower hypoglycemia rate and less weight gain were associated with a value of €27.87 per month.

Keywords::

• Health economics
• willingness-to-pay
• type 2 diabetes
• basal insulin
• insulin detemir
• NPH insulin
• discrete choice experiments
• hypoglycemia

Transparency

Declaration of funding

Funding for this work was provided by the sponsor Novo Nordisk, Scandinavia. All authors were actively involved at all stages of the preparation of the manuscript.

Declaration of financial/other relationships

JJ, MR, and OT have been involved in Novo Nordisk advisory boards and as consultants to Novo Nordisk, Scandinavia. ÅE and SL are employees of Novo Nordisk, Scandinavia.

Acknowledgments

Editorial assistance was provided by John Clarke and Martin Gilmour (ESP Bioscience, Crowthorne, UK) funded by Novo Nordisk, Scandinavia.